2BB score and signals
Nektar Therapeutics’s current 2BB score is 36 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|
| Activity | 56 | Moderate |
| Momentum | 39 | Weakening |
| Financial strength | 2 | Very Weak |
| Quality | 80 | Very Strong |
| Risk | 46 | Moderate |
Company facts
| Headquarters | San Francisco, California, United States |
| Founded | 1990 |
| Employees | 63 |
| 52-week range | $23.68 – $109.00 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|
| 2026-11-04 | — | -2.1744 | — | $10.63M |
| 2026-08-13 | — | -2.0243 | — | $10.63M |
| 2026-05-07 | -1.82 | -1.6267 | $10.86M | $10.85M |
| 2026-03-12 | -1.78 | -2.5236 | $21.81M | $10.61M |
Related companies
2BBBullish & Bearish